Oxford University Innovation Update Q1 2019
Nightstar's supermassive acquisition leads on an active quarter for the Oxford University innovation community.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Nightstar's supermassive acquisition leads on an active quarter for the Oxford University innovation community.
The Oxford University spinout secures investment from Centrica Innovations to support growth.
Development of a vaccine candidate with potential to save millions worldwide will be accelerated in commercialisation deal with Blue Water Vaccines.
Oxford University Innovation breaks its own spinout generation record as the spinout community attracts more investment than ever before.
The Oxford University spinout plans to use the investment to fuel its structural mass spectrometry to identify new medicines.
The University of Oxford spinout also inks clinical paper in Lancet Psychiatry, appoints CEO and sets up Oxford HQ and London development hub.
The Oxford University spinout will use the investment to further develop its exosome technology, capable of delivering drugs to previously inaccessible parts of the body.
Oxford University spinout external investment nears £1.9bn since 2011 - £506m of which was in the past twelve months.
Oxford Sciences Innovation leads round into Orbit Discovery, an Oxford University spinout developing a peptide platform.
Momentum behind the Oxford innovation ecosystem keeps building, with a third of spinouts formed over OUI's 30 year history created in the past three years.